April 13 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] targets a net profit of 300 million euro ($331 million) in 2023, it said on Thursday.
"In 2023, we expect Krka Group’s sales of products and services to reach 1.755 billion, and exports to account for 94% of total sales," the pharmaceuticals company said in a filing with the Ljubljana Stock Exchange.
Prescription pharmaceuticals are expected to account for an estimated 82% of overall sales, while investments are planned at 130 million euro, primarily in expansion and technological upgrades, Krka said.
Recruitment in Slovenia and abroad are expected to increase the total number of employees by 2% this year, Krka noted.
Krka recorded a consolidated net profit of 363.6 million euro in 2022, up 18% on an annual basis, while consolidated sales revenue increased by 10% to 1.717 billion euro.
($ = 0.90728 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here